It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.
It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.
Zalicus CEO Mark Corrigan told Scrip that the Cambridge, Massachusetts-based company will refocus its attention on its pain drug candidates...
Swiss major confident that new oncology drugs will fill revenue gap.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
Multi-blockbuster falls short in a giant cell arteritis study.
CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.
Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.
Bharatt Chowrira departs days after firm’s chair stepped down.
